ARTV Artiva Biotherapeutics, Inc.

NEUTRAL Impact: 3/10 8-K
Horizon months Filed Feb 24, 2026 Processed 3mo ago SEC 0001193125-26-067509
Final — all horizons settled through T+60d
ARTV ▲ +55.86% at T+60d
NEUTRAL call ✓ call won +55.86% · α vs SPY +48.91% · entry $5.03 → $7.84
Last close $6.80 (close Jun 8) · +35.19% from $5.03 entry
Entry anchored
Feb 24, 03:59 PM ET
via Databento tick
T+1d
+8.35%
call +8.35% · α +8.90%
$5.45
settled 4mo ago
T+5d
+8.55%
call +8.55% · α +9.65%
$5.46
settled 3mo ago
T+20d
+8.55%
call +8.55% · α +13.78%
$5.46
settled 3mo ago
T+60d
+55.86%
call +55.86% · α +48.91%
$7.84
settled 21d ago

Price Chart

Loading chart...

Executive Summary

Artiva Biotherapeutics appointed Thad Huston as Chief Financial Officer effective February 18, 2026. Huston receives an annual base salary of $540,000 and an inducement grant of 220,000 restricted stock units, with vesting over four years. The appointment reflects a strategic leadership addition in the biotech firm's financial management.

Actionable Insight

Monitor for future financial disclosures that may reflect the cost of this executive hire; watch for potential stock dilution from RSU issuance once Form S-8 is filed.

Key Facts

  • Thad Huston appointed CFO effective February 18, 2026
  • Annual base salary of $540,000 with 40% target bonus
  • Inducement grant of 220,000 RSUs under 2025 Inducement Plan
  • RSUs vest over four years: 25% on February 15, 2027, then quarterly
  • Employment Agreement includes severance terms for termination without Cause or for Good Reason

Financial Impact

Approximately $540,000 annual cash compensation plus $2.2 million in RSUs (based on current market value assumptions, not disclosed in filing)

operating expensesshare dilutioncompensation expense

Risk Factors

  • Potential dilution from issuance of 220,000 RSUs
  • Leadership transition risk during integration period
  • Increased operating expenses from new executive compensation

Market Snapshot

Exchange
Nasdaq

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (ARTV) — Batch item 10001193125-26-067509
Document: 0001193125-26-067509-index-headers.html0001193125-26-067509
Document: 0001193125-26-067509-index.html0001193125-26-067509
Document: 0001193125-26-067509.txt0001193125-26-067509
8-K Filing (ARTV) — Batch item 50001193125-26-067509
Document: 0001193125-26-067509-index-headers.html0001193125-26-067509
Document: 0001193125-26-067509-index.html0001193125-26-067509
Document: 0001193125-26-067509.txt0001193125-26-067509
13 reports for ARTV
Performance horizon
50% Hit rate 3 of 6 directional calls best @ T+5▲ +13.02%May 8, 2026
Filters
Rows
Reports for ARTV — sortable, filterable
Type Now
Jun 8, 2026
1d ago
Press Release
BULLISH ★ 7/10
$6.84 awaiting T+5awaiting T+5—$6.80 (−0.51%)
May 20, 2026
21d ago
Insider Cluster
BEARISH ★ 5/10
$7.84 $7.61▲ +2.93%▲ +4.74%$6.80 (+13.27%)
May 19, 2026
21d ago
Press Release
BULLISH ★ 8/10
$7.84 $7.63▼ −2.68%▼ −3.92%$6.80 (−13.27%)
May 19, 2026
21d ago
8-K
NEUTRAL ★ 3/10
$8.55 $7.85▼ −8.19%▼ −10.43%$6.80 (−20.47%)
May 19, 2026
21d ago
Press Release
NEUTRAL ★ 4/10
$8.55 $7.85▼ −8.19%▼ −10.43%$6.80 (−20.47%)
May 18, 2026
22d ago
144
NEUTRAL ★ 2/10
$8.55 $7.63▼ −10.76%▼ −13.06%$6.80 (−20.47%)
May 18, 2026
22d ago
144
NEUTRAL ★ 2/10
$8.55 $7.63▼ −10.76%▼ −13.06%$6.80 (−20.47%)
May 8, 2026
4w ago
8-K
BEARISH ★ 7/10
$10.60 $9.22▲ +13.02%▲ +12.93%$6.80 (+35.85%)
May 8, 2026
4w ago
8-K
BULLISH ★ 8/10
$10.89 $10.68▼ −1.93%▼ −3.39%$6.80 (−37.56%)
May 8, 2026
4w ago
Press Release
BULLISH ★ 7/10
$10.89 $10.68▼ −1.93%▼ −3.39%$6.80 (−37.56%)
Showing 10 of 13

US Market Status

Market Closed — Opens in 5h 10m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access